What exactly did Craig-Hallum do in the IRD analyst rating on March 11, 2026?

Craig-Hallum **reiterated a Buy** on Opus Genetics, Inc. (IRD) on **March 11, 2026**. The note described continued upside opportunity and did not post a new price target in the StreetInsider summary.

How should investors read a maintained IRD analyst rating versus an upgrade?

A maintained IRD analyst rating confirms an analyst’s prior view but does not add new bullish signal like an upgrade. It supports existing conviction but may not trigger immediate stock moves without fresh catalysts.

Did the Craig-Hallum note include an IRD price target or new financials?

The StreetInsider item for Craig-Hallum’s note did not list a specific IRD price target or new financial projections, so no fresh target accompanies the maintained Buy.

How significant is one maintained IRD analyst rating for small-cap investors?

For small-cap stocks like IRD with **$345,510,642** market cap, a single maintained IRD analyst rating adds useful perspective but offers limited consensus. Investors should combine it with company updates and sector trends.

Analyst Ratings

Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026

ByDanny Kontos March 12, 2026

Craig-Hallum maintained a Buy rating on Opus Genetics, Inc. (IRD) on March 11, 2026 at 09:17 AM. This IRD analyst rating reiteration highlights the firm’s view that the stock has material upside even as coverage remains limited. The note on StreetInsider records a price change of -1.18% ($-0.06) since the prior close and lists the price at time as N/A. We place this action in the context of Opus Genetics’ market cap of $345,510,642 and the broader analyst landscape for small-cap therapeutics.